FDA
-
-
-
-
-
-
-
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
-
-
-
-
-
-
-
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
-
-
-
-
-
-
-
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Rezolute (rzlt)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Rezolute (RZLT)
-
-
-
-
-
-
-
Rezolute Inc. (RZLT): FDA Grants Orphan Drug Designation to Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
-
-
-
-
-
-
-
Rezolute (RZLT) PT Raised to $15 at BTIG
-
323,147 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

